Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ... [Yahoo! Finance]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Yahoo! Finance
SPINRAZA Royalties: $57 million for Q3 2024; $152 million year-to-date. WAINUA Product Sales: $23 million for Q3 2024; $44 million year-to-date, with a 44% increase in Q3 compared to Q2. Operating Expenses: SG&A expenses increased 13% for Q3 2024 and 26% year-to-date, driven by higher sales and marketing expenses. Cash Position: Projected to end 2024 with $2.2 billion in cash following a recent equity offering. Employee Base: Over 1,000 employees as of the report. 2024 Revenue Guidance: Expected to exceed $575 million. Recent Milestone Payment: $30 million from AstraZeneca for UK approval of WAINUA. Warning! GuruFocus has detected 3 Warning Signs with IONS. Release Date: November 06, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Ionis Pharmaceuticals Inc ( NASDAQ:IONS ) is on the verge of its first independent launch with olezarsen, targeting familial chylomicronemia syndrome (FCS), a rare disease with no
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Company News for Nov 7, 2024 [Yahoo! Finance]Yahoo! Finance
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its price target lowered by analysts at Wells Fargo & Company from $82.00 to $77.00. They now have an "overweight" rating on the stock.MarketBeat
- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.MarketBeat
- Ionis to present at upcoming investor conferencesPR Newswire
IONS
Earnings
- 11/6/24 - Beat
IONS
Sec Filings
- 11/12/24 - Form 144
- 11/12/24 - Form 144
- 11/12/24 - Form 144
- IONS's page on the SEC website